PYGM and IGBP1

Data Source:
BioGRID (two hybrid)

		PYGM	IGBP1
Description		glycogen phosphorylase, muscle associated	immunoglobulin binding protein 1
Image
GO Annotations	Cellular Component	Cytoplasm Cytosol Extracellular Exosome	Cytoplasm Cytosol
	Molecular Function	Nucleotide Binding Protein Binding Glycogen Phosphorylase Activity Pyridoxal Phosphate Binding Linear Malto-oligosaccharide Phosphorylase Activity SHG Alpha-glucan Phosphorylase Activity	Protein Binding Protein Phosphatase Regulator Activity Protein Phosphatase 2A Binding
	Biological Process	Glycogen Metabolic Process Glycogen Catabolic Process	Negative Regulation Of Transcription By RNA Polymerase II Signal Transduction Negative Regulation Of Stress-activated MAPK Cascade Response To Tumor Necrosis Factor Regulation Of Dephosphorylation B Cell Activation Negative Regulation Of Cysteine-type Endopeptidase Activity Involved In Apoptotic Process Regulation Of Phosphoprotein Phosphatase Activity Regulation Of Microtubule-based Movement Response To Interleukin-1
Pathways		Glycogen breakdown (glycogenolysis) Glycogen breakdown (glycogenolysis)
Drugs		Pyridoxal phosphate Beta-D-Glucopyranose Spirohydantoin (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione alpha-D-glucose 6-phosphate N-beta-D-glucopyranosylacetamide Monofluorophosphate ion Beta-D-Glucose 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Nojirimycine Tetrazole Indirubin-5-sulphonate 2-Deoxy-Glucose-6-Phosphate C-(1-hydrogyl-beta-D-glucopyranosyl) formamide alpha-D-glucopyranosyl-2-carboxylic acid amide alpha-D-glucose-1-phosphate 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole N-acetyl-N'-beta-D-glucopyranosyl urea 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole CP-320626 (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Alvocidib 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium N(6)-(pyridoxal phosphate)-L-lysine Heptulose-2-Phosphate N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine Dexfosfoserine 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide Inosinic Acid 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
Diseases		Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)	Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia
GWAS		Urate levels ( 21768215)
Interacting Genes		29 interacting genes: AGTPBP1 ARID1B CDC42BPB CLASP2 DNM2 FAM110A IGBP1 INTS4 LMNA NIPSNAP2 NTAQ1 PDE4DIP POMP PPP1CA PPP1R3B PPP2CA PRKAB2 PYGB PYGL S100A1 SGCG SRP72 TOP1 TRAPPC2 TRIM54 TRIM55 TRIM63 TTN WWP1	12 interacting genes: APP HSPB1 LINC01257 MID1 MID2 PPP2CA PPP4C PPP6C PYGM REXO5 S100A13 SHOX
Entrez ID		5837	3476
HPRD ID		01986	02140
Ensembl ID		ENSG00000068976	ENSG00000089289
Uniprot IDs		P11217	P78318
PDB IDs		1Z8D	4IYP
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?